1887
Research Open Access
Like 0

Abstract

Background

According to the World Health Organization, hepatitis C virus (HCV) infection should be under control by 2030.

Aim

Our aim was to describe the size and temporal changes in reported cases of chronic HCV infection in Denmark and Sweden and to estimate the size of the hidden (undiagnosed) population born before 1965.

Methods

We extracted all HCV infections reported to national surveillance systems in Denmark and Sweden from 1990 to 2020. Prediction of the size of the hidden HCV-infected population was restricted to the cohort born before 1965 and cases reported up to 2017. We applied a model based on removal sampling from binomial distributions, estimated the yearly probability of diagnosis, and deducted the original HCV-infected population size.

Results

Denmark (clinician-based) reported 10 times fewer hepatitis C cases annually than Sweden (laboratory and clinician-based), peaking in 2007 (n = 425) and 1992 (n = 4,537), respectively. In Denmark, the birth year distribution was monophasic with little change over time. In recent years, Sweden has had a bimodal birth year distribution, suggesting ongoing infection in the young population. In 2017, the total HCV-infected population born before 1965 was estimated at 10,737 living persons (95% confidence interval (CI): 9,744–11,806), including 5,054 undiagnosed, in Denmark and 16,124 (95% CI: 13,639–18,978), including 10,580 undiagnosed, in Sweden.

Conclusions

The reporting of HCV cases in Denmark and Sweden was different. For Denmark, the estimated hidden population was larger than the current national estimate, whereas in Sweden the estimate was in line with the latest published numbers.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.50.2200243
2022-12-15
2024-06-13
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.50.2200243
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/50/eurosurv-27-50-5.html?itemId=/content/10.2807/1560-7917.ES.2022.27.50.2200243&mimeType=html&fmt=ahah

References

  1. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415.  https://doi.org/10.1016/S2468-1253(21)00472-6  PMID: 35180382 
  2. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021. Geneva: WHO; 2016. Available from: https://apps.who.int/iris/handle/10665/246177
  3. Hansen JF, Hallager S, Øvrehus A, Weis N, Brehm Christensen P, Pedersen C. Late presentation for care among patients with chronic hepatitis C: prevalence and risk factors. Open Forum Infect Dis. 2017;5(1):ofx257.  https://doi.org/10.1093/ofid/ofx257  PMID: 29367939 
  4. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435-44.  https://doi.org/10.1016/S2468-1253(19)30085-8  PMID: 30981685 
  5. Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150-66.  https://doi.org/10.1111/add.14393  PMID: 30035835 
  6. Øvrehus A, Nielsen S, Hansen JF, Holm DK, Christensen P. Test uptake and hepatitis C prevalence in 5483 Danish people in drug use treatment from 1996 to 2015: a registry-based cohort study. Addiction. 2019;114(3):494-503.  https://doi.org/10.1111/add.14479  PMID: 30347471 
  7. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34-59.  https://doi.org/10.1111/jvh.12248  PMID: 24713005 
  8. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32. PMID: 22895429 
  9. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817-22.  https://doi.org/10.7326/0003-4819-157-9-201211060-00529  PMID: 22910836 
  10. Statistics Denmark. FOLK3: Folketal 1. januar efter fødselsdag, fødselsmåned og fødselsår. [Population on 1 January by day, month and year of birth]. Copenhagen: Danmarks Statistik. [Accessed:29 Nov 2022]. Danish. Available from: https://www.statistikbanken.dk/FOLK3
  11. Statistics Sweden (SCB). Population per region by foreign or Swedish background and sex. Year 2015-2020. Solna: SCB. [Accessed: 29 Nov 2022]. Available from: https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101Y/FolkmDesoBakgrKonN
  12. Nielsen S, Hansen JF, Hay G, Cowan S, Jepsen P, Omland LH, et al. Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers. PLoS One. 2020;15(9):e0238203.  https://doi.org/10.1371/journal.pone.0238203  PMID: 32881877 
  13. Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50(2):233-44.  https://doi.org/10.3109/00365521.2014.990505  PMID: 25515032 
  14. Norda R, Duberg AS, Sönnerborg A, Olcén P. Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. Scand J Infect Dis. 1995;27(5):449-52.  https://doi.org/10.3109/00365549509047044  PMID: 8588133 
  15. Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors--the role of parenteral and sexual transmission. Scand J Infect Dis. 1995;27(2):99-104.  https://doi.org/10.3109/00365549509018987  PMID: 7544914 
  16. Hoffmann G, Berglund G, Elmståhl S, Eriksson S, Verbaan H, Widell A, et al. Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population. Scand J Gastroenterol. 2000;35(8):861-5.  https://doi.org/10.1080/003655200750023246  PMID: 10994626 
  17. Millbourn C, Lybeck C, Fadl H, Fredlund H, Lindahl K, Duberg AS. Screening for HCV in pregnant women and their partners. J Hepatol. 2017;66(1):S404-5.  https://doi.org/10.1016/S0168-8278(17)31167-4 
  18. Hansen N, Cowan S, Christensen PB, Weis N, DANHEP-styregruppen. [Reporting chronic hepatitis B and C in Denmark]. Ugeskr Laeger. 2008;170(18):1567-70. Danish. PMID: 18454929 
  19. Folkhälsomyndigheten. Falldefinitioner vid anmälan enligt smittskyddslagen. [Case definitions according to the infection protection act]. Solna: Folkhälsomyndigheten; 2022 Swedish. Available from: https://www.folkhalsomyndigheten.se/contentassets/d109fac1689846edb6ce7292c0588e39/falldefinitioner-anmalan-smittskyddslagen.pdf
  20. Christensen PB, Søholm J, Øvrehus A. [From treating in the dark towards eliminating hepatitis C]. Ugeskr Laeger. 2021;183(46):V02210145. Danish. PMID: 34796863 
  21. Socialstyrelsen. Statistikdatabas för läkemedel. [Statistics database for medicines]. Stockholm: Socialstyrelsen. [Accessed: 29 Nov 2022]. Swedish. Available from: https://sdb.socialstyrelsen.se/if_lak/val.aspx
  22. Blach S, Blomé M, Duberg AS, Jerkeman A, Kåberg M, Klasa PE, et al. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. Liver Int. 2021;41(9):2024-31.  https://doi.org/10.1111/liv.14978  PMID: 34051065 
  23. Folkhälsomyndigheten (Fohm). Hepatit C – sjukdomsstatistik. [Hepatitis C disease statistics]. Solna: Fohm. [Accessed: 29 Nov 2022]. Swedish. Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistik-a-o/sjukdomsstatistik/hepatit-c
  24. Ledberg A, Wennberg P. Estimating the size of hidden populations from register data. BMC Med Res Methodol. 2014;14(1):58.  https://doi.org/10.1186/1471-2288-14-58  PMID: 24766871 
  25. Hsieh YH, Chen CW, Lee SM. Empirical Bayes approach to estimating the number of HIV-infected individuals in hidden and elusive populations. Stat Med. 2000;19(22):3095-108.  https://doi.org/10.1002/1097-0258(20001130)19:22<3095::AID-SIM605>3.0.CO;2-W  PMID: 11113945 
  26. Rodriguez de Rivera O, McCrea R. Removal modelling in ecology: A systematic review. PLoS One. 2021;16(3):e0229965.  https://doi.org/10.1371/journal.pone.0229965  PMID: 33661897 
  27. Human Mortality Database (HMU). Sweden. Total population. [Accessed: 29 Nov2022]. Available from: https://www.mortality.org/Country/Country?cntr=SWE
  28. Christiansen KM, Mössner BK, Hansen JF, Jarnbjer EF, Pedersen C, Christensen PB. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One. 2014;9(11):e111912.  https://doi.org/10.1371/journal.pone.0111912  PMID: 25369038 
  29. Duberg AS, Törner A, Daviðsdóttir L, Aleman S, Blaxhult A, Svensson A, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008;15(7):538-50.  https://doi.org/10.1111/j.1365-2893.2008.00982.x  PMID: 18397223 
  30. Batyrbekova N, Aleman S, Lybeck C, Montgomery S, Duberg AS. Hepatitis C virus infection and the temporal trends in the risk of liver cancer: a national register-based cohort study in Sweden. Cancer Epidemiol Biomarkers Prev. 2020;29(1):63-70.  https://doi.org/10.1158/1055-9965.EPI-19-0769  PMID: 31719064 
  31. Zippin C. An evaluation of the removal method of estimating animal populations. Biometrics. 1956;12(2):163-89.  https://doi.org/10.2307/3001759 
  32. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill. 2008;13(21):18882.  https://doi.org/10.2807/ese.13.21.18882-en  PMID: 18761966 
  33. Christensen PB, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, et al. Hepatitis C prevalence in Denmark -an estimate based on multiple national registers. BMC Infect Dis. 2012;12(1):178.  https://doi.org/10.1186/1471-2334-12-178  PMID: 22866925 
  34. Duberg AS, Hansdotter F, How AL, Holmström A, Lesko B. [Important with generous sampling for hepatitis C after blood transfusion. The National Board of Health and Welfare’s new recommendation for risk groups]. Lakartidningen. 2013;110(34-35):1477-9. Swedish. PMID: 24044185 
  35. Lidman C, Norden L, Kåberg M, Käll K, Franck J, Aleman S, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis. 2009;41(9):679-84.  https://doi.org/10.1080/00365540903062143  PMID: 19521924 
  36. Ydreborg M, Söderström A, Håkanson A, Alsiö A, Arnholm B, Malmström P, et al. Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scand J Infect Dis. 2011;43(6-7):522-7.  https://doi.org/10.3109/00365548.2011.562526  PMID: 21375426 
  37. Christensen PB, Krarup HB, Niesters HG, Norder H, Schaffalitzky de Muckadell OB, Jeune B, et al. Outbreak of Hepatitis B among injecting drug users in Denmark. J Clin Virol. 2001;22(1):133-41.  https://doi.org/10.1016/S1386-6532(01)00175-5  PMID: 11418361 
  38. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):537-41. PMID: 21544042 
  39. Ovrehus ALH. Towards elimination of hepatitis C. Odense: Syddansk Universtitet; 2019. Ph.D. thesis. Available from: https://findresearcher.sdu.dk/ws/portalfiles/portal/173415802/Towards_Elimination_of_Hepatitis_for_print_ny.pdf
  40. Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, et al. Incidence, prevalence and risk factors for hepatitis C in Danish prisons. PLoS One. 2019;14(7):e0220297.  https://doi.org/10.1371/journal.pone.0220297  PMID: 31348813 
  41. Sundhedsstyrelsen. Stofmisbrugsbehandling–efterspørgsel og tilgængelighed. [Drug use treatment—demand and availability]. Copenhagen: Sundhedsstyrelsen; 2019. Danish. Available from: https://www.sst.dk/-/media/Udgivelser/2019/Stoffer/Stofmisbrugsbehandling-efterspoergsel-og-tilgaengelighed-Narkotikasituationen-i-DK---delrapport-3.ashx?sc_lang=da&hash=147A373DB9795962A7178FE5BE33FE7F
  42. Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, et al. The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination. Clin Infect Dis. 2019;69(12):2218-27.  https://doi.org/10.1093/cid/ciz714  PMID: 31352481 
/content/10.2807/1560-7917.ES.2022.27.50.2200243
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error